A six-month study of pergolide and levodopa in de novo Parkinson's disease patients

Clinical Neuropharmacology

Volumn 21, Issue 6, 1998, Pages 358-362

  Kulisevsky, Jaime ^a,b   López Villegas, Dolores ^a   García Sánchez, Carmen ^a   Barbanoj, Manel ^a   Gironell, Alexandre ^a   Pascual Sedano, Berta ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Dopamine agonists; Levodopa; Parkinson's disease; Pergolide; Side effects

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOMPERIDONE; LORAZEPAM; PERGOLIDE;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; FEMALE; HUMAN; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL HALLUCINATION;

ADULT; AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; PERGOLIDE; TREATMENT OUTCOME;

EID: 0344074013     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lieberman A. Dopamine agonists in Parkinson's disease. In: Koller WC, Paulson GP, eds. Therapy of Parkinson's Disease. New York: Marcel Dekker, 1995:199-207.
2. Uitti R, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-388.
3. Lees A, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
4. Grimes JD, Delgado MR. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease. Clin Neuropharmacol 1985; 8:73-77.
5. Sage JI, Duvoisin RC. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 1985;8:260-265.
6. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up. Neurology 1987;37:826-828.
7. Hely MA, Morris JGL, Rail DD, et al. The Sidney multicenter study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1989;52:324-328.
8. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
9. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-339.
10. Parkinson's Disease Research Group. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
11. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet ® in Parkinson's disease. Mov Disord 1994;9:40-47.
12. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62: 1034-1038.
13. Rinne UK. Early dopamine agonist treatment in Parkinson's disease. Adv Neurol 1990;53:417-419.
14. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
15. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson's disease. Neurology 1994;44(Suppl 10):S9-S52.
16. Olanow CW, Koller WC PD. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 1998;50(Suppl 3):S1-S57.
17. Rinne UK. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 1986;45:519-523.
18. Adler CH, Sethi KD, Hauser RA. Et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
19. Hubble JP Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
20. Shannon KM, Bennett JP, Friedman JH, et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
21. Fahn S, Elston RL and members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol 2. New York: MacMillan, 1987:153-163.
22. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
23. Olanow CW, Fahn S, Muenter M, et al. A multi-center, double blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
24. Parkes JD, Debono AG, Marsden CD. Bromocriptine in parkinsonism: long term treatment, dose response and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976;39:1101-1108.
25. Calne DB, Plotkin C, Williams AC, Nutt JG, Neophytides A, Teychenne PF. Long-term treatment of Parkinsonism with bromocriptine. Lancet 1978;1:735-738.
26. Staal-Schreinemachers AL, Wesseling H, Karnphuis DJ, et al. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986;36:291-293.
27. Stocchi F, Keens J. The efficacy at 6 months of ropinirole versus bromocriptine as early therapy in parkinsonian patients (abstract). J Neurol 1996;243(Suppl 2):S38.
28. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994;9:431-436.
29. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45:S13-S21.